The new material targets manufacturing of peptide therapeutics for diabetes, obesity and cancer, and is built to fit existing chromatography setups.
Recap by typeshit. Full story at Yahoo Finance.
The EMA's CHMP amended its type 2 diabetes indication, and Italian diabetologists say Italy could be the first European country to offer the once-weekly combo.
26:19
A personal update from TakingWeightOff on life after stopping tirzepatide, three weeks in, and what caught them off guard.
Nyah Phengsitthy reports Lilly is staking out a new battlefront around an unapproved obesity treatment. The full story has the details.
A history of drug advertising, from opium-laced tonics and Radithor to the 1938 law after Elixir Sulfanilamide killed over 100 people. Semaglutide is mostly a hook.
GLP-1 drugs come with side effects from hair loss to severe stomach trouble. SheKnows looks at a newer drug class researchers hope will be easier to tolerate.
BharatTechIND reports the drugmaker is widening its semaglutide lineup to get around supply problems with Obeda and grow in India's weight loss market.
Loading…